These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38293058)

  • 1. Lecanemab Blocks the Effects of the Aβ/Fibrinogen Complex on Blood Clots and Synapse Toxicity in Organotypic Culture.
    Singh PK; Pires ENS; Chen ZL; Torrente D; Calvano M; Sharma A; Strickland S; Norris EH
    bioRxiv; 2024 Jan; ():. PubMed ID: 38293058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lecanemab blocks the effects of the Aβ/fibrinogen complex on blood clots and synapse toxicity in organotypic culture.
    Singh PK; Simões-Pires EN; Chen ZL; Torrente D; Calvano M; Sharma A; Strickland S; Norris EH
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2314450121. PubMed ID: 38621133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease.
    Chen ZL; Singh PK; Calvano M; Norris EH; Strickland S
    Proc Natl Acad Sci U S A; 2023 Sep; 120(36):e2309389120. PubMed ID: 37639602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.
    Johannesson M; Söderberg L; Zachrisson O; Fritz N; Kylefjord H; Gkanatsiou E; Button E; Svensson AS; Rachalski A; Nygren P; Osswald G; Lannfelt L; Möller C
    Mol Cell Neurosci; 2024 Sep; 130():103949. PubMed ID: 38906341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperhomocysteinemia exacerbates Alzheimer's disease pathology by way of the β-amyloid fibrinogen interaction.
    Chung YC; Kruyer A; Yao Y; Feierman E; Richards A; Strickland S; Norris EH
    J Thromb Haemost; 2016 Jul; 14(7):1442-52. PubMed ID: 27090576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization.
    Ahn HJ; Zamolodchikov D; Cortes-Canteli M; Norris EH; Glickman JF; Strickland S
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21812-7. PubMed ID: 21098282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.
    Yoon CH; Groff C; Criss O
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen and altered hemostasis in Alzheimer's disease.
    Cortes-Canteli M; Zamolodchikov D; Ahn HJ; Strickland S; Norris EH
    J Alzheimers Dis; 2012; 32(3):599-608. PubMed ID: 22869464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
    Vitek GE; Decourt B; Sabbagh MN
    Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
    McDade E; Cummings JL; Dhadda S; Swanson CJ; Reyderman L; Kanekiyo M; Koyama A; Irizarry M; Kramer LD; Bateman RJ
    Alzheimers Res Ther; 2022 Dec; 14(1):191. PubMed ID: 36544184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen.
    Cajamarca SA; Norris EH; van der Weerd L; Strickland S; Ahn HJ
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14482-14492. PubMed ID: 32518112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The basis of anti-Aβ antibody therapy: The toxicity of Aβ aggregates and the mechanism of action of anti-Aβ antibodies.
    Ono K; Noguchi-Shinohara M; Watanabe-Nakayama T
    Intern Med; 2024 Oct; ():. PubMed ID: 39370248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Leaky Blood-Brain Barrier to Fibrinogen Contributes to Oxidative Damage in Alzheimer's Disease.
    McLarnon JG
    Antioxidants (Basel); 2021 Dec; 11(1):. PubMed ID: 35052606
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.